Marc Hoffmann, Associate Professor; Director, Lymphoma Program
Marc S Hoffmann, MD serves as the Director of the Lymphoma program and Medical Director for Lean and Quality Improvement at the University of Kansas Cancer Center. As the Director of Lymphoma he directs the clinical and basic science research in lymphoma, oversees care delivery for lymphoma patients, and cares for lymphoma patients on both and inpatient and outpatient basis. He serves as the principal investigator on multiple national and international trials in CLL and a wide variety of lymphoma subtypes. As Medical Director for Lean and Quality Improvement his critical duties involve interfacing with the Cancer Center executive team to set strategic priorities, translating those priorities into specific Lean initiatives, and supervising the execution and monitoring of all Lean activities in the Cancer Center. Selected projects include improving safety and delivery of oral chemotherapy, increasing efficiency and capacity of oncology infusion suites, developing home infusion services for cancer therapy, and improving exam space utilization.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:AbbVieDate added:04/05/2024Date updated:04/05/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:ADC TherapeuticsDate added:04/05/2024Date updated:04/05/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BeiGeneDate added:04/05/2024Date updated:04/05/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GenentechDate added:04/05/2024Date updated:04/05/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Astra-ZenecaDate added:04/05/2024Date updated:04/05/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:NovartisDate added:04/05/2024Date updated:04/05/2024
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:JanssenDate added:04/05/2024Date updated:04/05/2024